stockrow
Saturday 7 November 2026
Export HCWB’s income statement to Excel — free account
HCW Biologics Inc.
HCWB Healthcare Biotechnology
HCW Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54,200.00, down 97.9% from fiscal 2024.
- Revenue
- +1,954.6%
- EPS
- +71.6%
- Free cash flow
- −20.8%
- Total debt
- −3.34%
Quarter to June 2026, against a year earlier
1.02
0.02
−1.92%
Follow HCWB
Alert me
HCW Biologics Inc. (HCWB) P/E ratio
HCW Biologics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 9.1× (September 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 14 more quarters | Free account |
Against its own ten years
Low 0.0×
High 9.1×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| HCWB HCW Biologics Inc. | n/m |
| APVO Aptevo Therapeutics Inc. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)